PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year. Crossover investors are the most prolific backers...

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Feb. 1 in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors...

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Thursday in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors Adams...

Roche (SIX:ROG; OTCQX:RHHBY) disclosed in its Thursday earnings report that it will discontinue development of RG6047 (GDC-0927). The selective estrogen receptor degrader was in a Phase I trial to treat ER-positive, HER2-negative metastatic breast cancer....

Robert Mulroy and Debasish Roychowdhury launched newco Partner Therapeutics Inc. (Boston, Mass.), which has a portfolio of approved and late-stage cancer therapies. Chairman and CEO Mulroy was co-founder, CEO and president of Merrimack Pharmaceuticals Inc....

Roche said it discontinued development of RG6046, which it gained through its acquisition of Seragon Pharmaceuticals Inc. in 2014. The pharma had studied RG6046 in a Phase II trial to treat estrogen receptor-positive, HER2-negative metastatic...